Stephen P Ethier

List of Publications by Year
in descending order

39	4,750	218592	315616
papers	citations	26 h-index	38 g-index

39	39	39	9085
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Estrogen Receptor Positive Breast Cancer: 8p11-p12 Amplicon and Therapeutic Response. , 2021, , .		0
2	Development and implementation of the SUM breast cancer cell line functional genomics knowledge base. Npj Breast Cancer, 2020, 6, 30.	2.3	4
3	Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer. BMC Cancer, 2019, 19, 491.	1.1	42
4	Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS ONE, 2019, 14, e0224420.	1.1	36
5	Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models. BMC Cancer, 2018, 18, 1233.	1.1	7
6	ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen. Vaccine, 2018, 36, 6262-6269.	1.7	6
7	Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget, 2018, 9, 23878-23889.	0.8	11
8	Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3. Breast Cancer Research and Treatment, 2017, 164, 349-358.	1.1	19
9	MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 6641-6650.	0.4	91
10	Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nature Communications, 2016, 7, 13050.	5.8	135
11	MYC Is a Crucial Mediator of TGFÎ²-Induced Invasion in Basal Breast Cancer. Cancer Research, 2016, 76, 3520-3530.	0.4	12
12	Amplification of WHSC1L1 regulates expression and estrogenâ€independent activation of ERÎ± in SUMâ€44 breast cancer cells and is associated with ERÎ± overâ€expression in breast cancer. Molecular Oncology, 2016, 10, 850-865.	2.1	41
13	Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. Oncotarget, 2016, 7, 36138-36153.	0.8	6
14	The culture of cell culture practices and authenticationâ€"Results from a 2015 Survey. BioTechniques, 2015, 59, 189-90, 192.	0.8	25
15	Reproducibility: changing the policies and culture of cell line authentication. Nature Methods, 2015, 12, 493-497.	9.0	114
16	Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer. Advances in Cancer Research, 2015, 127, 253-281.	1.9	24
17	Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes. Experimental Cell Research, 2015, 332, 223-235.	1.2	88
18	Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Research, 2015, 17, 130.	2.2	41

#	Article	IF	Citations
19	Oncogenic signaling in amphiregulin and EGFRâ€expressing PTENâ€null human breast cancer. Molecular Oncology, 2015, 9, 527-543.	2.1	24
20	KAT6A, a Chromatin Modifier from the 8p11-p12 Amplicon is a Candidate Oncogene in Luminal Breast Cancer. Neoplasia, 2014, 16, 644-655.	2.3	37
21	SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression. Molecular Cancer Therapeutics, 2014, 13, 2713-2726.	1.9	51
22	Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Molecular Oncology, 2012, 6, 494-506.	2.1	136
23	ERLIN2 promotes breast cancer cell survival by modulating endoplasmic reticulum stress pathways. BMC Cancer, 2012, 12, 225.	1.1	55
24	Transforming Properties of 8p11-12 Amplified Genes in Human Breast Cancer. Cancer Research, 2010, 70, 8487-8497.	0.4	84
25	HER-2 Signaling, Acquisition of Growth Factor Independence, and Regulation of Biological Networks Associated with Cell Transformation. Cancer Research, 2010, 70, 7862-7873.	0.4	19
26	Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. Journal of Cellular Physiology, 2007, 210, 720-731.	2.0	60
27	A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 2006, 10, 515-527.	7.7	2,729
28	Multiple Interacting Oncogenes on the 8p11-p12 Amplicon in Human Breast Cancer. Cancer Research, 2006, 66, 11632-11643.	0.4	109
29	Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer. Molecular Cancer Research, 2005, 3, 655-667.	1.5	201
30	Genomic organization of the 8p11â¼p12 amplicon in three breast cancer cell lines. Cancer Genetics and Cytogenetics, 2004, 155, 57-62.	1.0	32
31	Genomic and Expression Analysis of the 8p11â€“12 Amplicon in Human Breast Cancer Cell Lines. Cancer Research, 2004, 64, 40-47.	0.4	116
32	Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Molecular Cancer Research, 2004, 2, 643-52.	1.5	46
33	Transforming Potential of Alternatively Spliced Variants of Fibroblast Growth Factor Receptor 2 in Human Mammary Epithelial Cells. Molecular Cancer Research, 2004, 2, 643-652.	1.5	89
34	Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Research, 2000, 2, 311-20.	2.2	62
35	erbB-2 Overexpression in Human Mammary Epithelial Cells Confers Growth Factor Independence*. Endocrinology, 1999, 140, 3615-3622.	1.4	45
36	Constitutive activation of pp125fak in newly isolated human breast cancer cell lines. Breast Cancer Research and Treatment, 1999, 54, 173-182.	1.1	45

#	Article	IF	Citations
37	erbB-2 Overexpression in Human Mammary Epithelial Cells Confers Growth Factor Independence. Endocrinology, 1999, 140, 3615-3622.	1.4	14
38	Human breast cancer cell lines as models of growth regulation and disease progression. Journal of Mammary Gland Biology and Neoplasia, 1996, 1, 111-121.	1.0	64
39	The influence of growth factors on the proliferative potential of normal and primary breast cancer-derived human breast epithelial cells. Breast Cancer Research and Treatment, 1991, 17, 221-230.	1.1	30